Trastuzumab containing regimens for early breast cancer (Q24200192)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22513938%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

meta-analysis

0 references

title

Trastuzumab containing regimens for early breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22513938%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22513938%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22513938%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Ludovica Tagliabue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22513938%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Elena Parmelli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22513938%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Vanna Pistotti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22513938%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Valentina Guarneri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22513938%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Lorenzo Moja

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22513938%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

publication date

18 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22513938%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

29 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22513938%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22513938%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

CD006243

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22513938%20AND%20SRC:MED&resulttype=core&format=json

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

29 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Calculating the number needed to treat for trials where the outcome is time to an event

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Evaluating non-randomised intervention studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

The discovery of receptor tyrosine kinases: targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

21 January 2018

Disappointing biotech

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Trials stopped early: too good to be true?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

First-line Herceptin monotherapy in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006243.PUB2

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

21 January 2018

1 reference

12 December 2020

Herceptin and early breast cancer: a moment for caution

1 reference

12 December 2020

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer

1 reference

12 December 2020

Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and

1 reference

12 December 2020

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

12 December 2020

Detecting and describing heterogeneity in meta-analysis

1 reference

12 December 2020

10.1002/14651858.CD006243.PUB2

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

28147

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22513938%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

28147

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22513938%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

PubMed publication ID

22513938

2 references

Consolidated OpenCitations Corpus – April 2017

28147

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22513938%20AND%20SRC:MED&resulttype=core&format=json